M. Bagot a, ⁎, F. Child b, P. Ortiz Romero c, R. Alvarez d, R. Stadler e, M. Weichenthal f, R. Alves g, M.G. Bernengo h, M. Beylot-Barry i, R. Cowan j, L.J. Geskin k, A.F. Pérez l, P. Hellemans m, Y. Elsayed n, C. Phelps n, A. Forslund m, M. Kamida o, P.L. Zinzani p
a Hôpital Saint-Louis, Paris, France
b Saint-Thomas’ Hospital, London, Royaume-uni
c Hospital Universitario 12 de Octubre, Madrid, Espagne
d Instituto Português de Oncologia, Lisboa, Portugal
e Johannes Wesling Medical Centre, Minden, Allemagne
f University Hospital of Schleswig-Holstein, Kiel, Allemagne
g Hospital Geral de Santo António, Porto, Portugal
h University of Turin, Department of Medical Sciences and Human Oncology Section of Dermatology, Turin, Italie
i Hôpital Haut-Lévêque, CHU de Bordeaux, Bordeaux, France
j Christie Hospital, Manchester, Royaume-Uni
k University of Pittsburgh, Pittsburgh, États-Unis
l Hospital General, Valencia, Espagne
m Janssen R&D, Beerse, Belgique
n Janssen R&D, Raritan, États-Unis
o Janssen Pharmaceutical K.K., Tokyo, Japon
p University of Bologna, Bologna, Italie